Home » Stocks » Pluristem Therapeutics

Pluristem Therapeutics, Inc. (PSTI)

Stock Price: $10.47 USD -0.24 (-2.24%)
Updated Oct 21, 2020 10:30 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 267.56M
Revenue (ttm) 23,000
Net Income (ttm) -29.15M
Shares Out 25.55M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $10.47
Previous Close $10.71
Change ($) -0.24
Change (%) -2.24%
Day's Open 10.75
Day's Range 10.47 - 10.87
Day's Volume 58,923
52-Week Range 2.82 - 13.29

More Stats

Market Cap 267.56M
Enterprise Value 222.80M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 25.55M
Float 20.31M
EPS (basic) -1.60
EPS (diluted) -1.60
FCF / Share -1.46
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.14M
Short Ratio 3.88
Short % of Float 5.64%
Beta 2.59
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11,632.94
PB Ratio 5.07
Revenue 23,000
Operating Income -29.48M
Net Income -29.15M
Free Cash Flow -26.64M
Net Cash 44.75M
Net Cash / Share 1.75
Gross Margin 100.00%
Operating Margin -128,156.52%
Profit Margin -126,747.80%
FCF Margin -115,821.74%
ROA -38.05%
ROE -74.82%
ROIC -130.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.00*
(33.72% upside)
Low
12.0
Current: $10.47
High
16.0
Target: 14.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2020201920182017201620152014201320122011
Revenue0.020.050.05-2.850.380.380.680.72-
Revenue Growth-57.41%8%--651.19%0%-44.18%-5.17%--
Gross Profit0.020.050.05-2.750.370.370.660.70-
Operating Income-29.48-35.53-33.73-28.02-23.32-25.27-27.85-22.22-15.03-11.11
Net Income-29.15-35.31-26.13-27.81-23.25-24.68-26.93-21.16-14.79-10.85
Shares Outstanding18.2012.3310.598.747.957.036.355.554.403.12
Earnings Per Share-1.60-2.90-2.50-3.20-2.90-3.50-4.20-3.80-3.40-3.50
Operating Cash Flow-26.37-29.45-21.38-21.61-18.52-20.61-19.12-16.89-3.28-5.76
Capital Expenditures-0.27-0.24-0.34-0.35-1.72-0.81-1.57-4.31-1.48-0.93
Free Cash Flow-26.64-29.69-21.72-21.96-20.24-21.42-20.69-21.20-4.76-6.69
Cash & Equivalents46.3424.4030.5926.6732.7553.1258.8254.2137.8142.83
Total Debt1.59---------
Net Cash / Debt44.7524.4030.5926.6732.7553.1258.8254.2137.8142.83
Assets65.5331.3138.9637.5345.9468.1674.0268.3247.4246.02
Liabilities9.439.4910.457.287.7910.0111.9010.859.682.59
Book Value56.1021.8228.5130.2538.1658.1462.1257.4737.7443.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Pluristem Therapeutics, Inc.
Country Israel
Employees 146
CEO Yaky Yanay

Stock Information

Ticker Symbol PSTI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTI

Description

Pluristem Therapeutics, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients unsuitable for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermittent claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has collaboration agreements with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions; and BIH Center for Regenerative Therapy and Berlin Center for Advanced Therapies to expand its framework and research agreement, as well as conduct a joint project evaluating the therapeutic effects of the registrant's patented PLX cell product candidates for treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.